Goal and Learning Outcomes

Upon successful completion of this activity, you should be better prepared to:

Discuss the inflammatory pathophysiology of MS as related to BTK
Describe the safety and efficacy of BTK inhibitors in the management of patients with relapsed-remitting and progressive forms of MS
Incorporate recent and emerging data into case-based treatment strategies for MS based on patient-specific needs


Claire S. Riley, MD
Karen L. K. Miller Assistant Professor of Neurology
Medical Director, Columbia Multiple Sclerosis Center
Division of Neuroimmunology
Department of Neurology
Columbia University Irving Medical Center
New York, NY

Stephen Krieger, MD, FAAN
Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY

Accreditation Information

This course is being provided by a Relias LLC strategic partner.  Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.